The use of digital technologies in adherence to anti-tuberculosis treatment
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
49 0
SM ISO690:2012
FIELDING, Katherine Linda, SUBBARAMAN, Ramnath, KHAN, Amera H., CELAN, Cristina, CHARALAMBOUS, Salome, FRANKE, Molly F., HUDDART, Sophie, KATAMBA, Achilles, LAW, Stephanie, STAGG, Helen Ruth. The use of digital technologies in adherence to anti-tuberculosis treatment. In: ERS Monograph, 2023, vol. 2023, pp. 170-184. ISSN 2312-508X. DOI: https://doi.org/10.1183/2312508X.10002223
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
ERS Monograph
Volumul 2023 / 2023 / ISSN 2312-508X /ISSNe 2312-5098

The use of digital technologies in adherence to anti-tuberculosis treatment

DOI:https://doi.org/10.1183/2312508X.10002223

Pag. 170-184

Fielding Katherine Linda12, Subbaraman Ramnath34, Khan Amera H.5, Celan Cristina6, Charalambous Salome2, Franke Molly F.7, Huddart Sophie8, Katamba Achilles910, Law Stephanie7, Stagg Helen Ruth1
 
1 London School of Hygiene and Tropical Medicine,
2 University of Witwatersrand,
3 Tufts University School of Medicine, Boston,
4 Tufts Medical Center, Boston,
5 TB REACH Initiative, Geneva,
6 Center for Health Policies and Studies (PAS),
7 Harvard Medical School, Boston,
8 University of California, San Francisco,
9 Makerere University, College of Health Sciences, Kampala,
10 Makerere University, Kampala
 
 
Disponibil în IBN: 25 martie 2024


Rezumat

Tuberculosis (TB) kills over 1.5 million people every year, particularly in low-and middle-income countries. Despite recent advances, regimens are at least several months in length, which can be problematic for people with TB. In the last decade, digital adherence technologies (DATs) have been used both to monitor and to promote dose taking. As interventions, DATs can be reminders for dose taking and generate digital dosing histories to help triage patients. The evidence for DATs improving treatment outcomes as a result of improving adherence is mixed. Emerging evidence suggests that people with TB value DAT functions that foster a feeling of being “cared for” by the health system. DATs should be embedded within, rather than used as the sole replacement for, comprehensive care packages. As monitors of dose taking, DATs provide rich dose-by-dose datasets for use in research and allow greater empowerment of people with TB than the directly observed therapy used previously. They may, however, not be a perfect proxy for adherence.